About BCAL Diagnostics
BCAL Diagnostics Limited is an Australian biotechnology company, founded in 2010 and headquartered in Sydney, Australia, and listed on the Australian Securities Exchange (ASX: BDX). For over a decade, BCAL has been developing early, non-invasive blood test based diagnostic technologies designed to complement mammograms and improve breast cancer screening outcomes for women worldwide.
BCAL’s NATA-accredited commercial laboratory, equipped with advanced Liquid Chromatography Mass Spectrometry (LCMS) technology, supports both ongoing research and the commercial rollout of its diagnostic test.
In 2025 BCAL entered into an exclusive licence partnership with US-based ClearNote Health Inc., providing access to the Avantect® pancreatic and ovarian cancer early detection blood tests across Australia. These epigenomics-based tests leverage artificial intelligence and advanced genomic analysis, and expand BCAL’s diagnostic portfolio beyond breast cancer and addressing cancers that are challenging to identify in early stages.
Through strategic collaborations with pathology networks and clinical partners, BCAL aims to provide nationwide access to innovative diagnostics that support earlier cancer detection regardless of location.
OUR VISION
BCAL Diagnostics aims to lead a global shift in breast cancer diagnosis by partnering with doctors to deliver non-invasive diagnostics that integrate seamlessly with clinical care
Our Values
Patient-Centred Innovation
We create accessible, non-invasive diagnostic tools that support informed decisions
Early Detection, Better Outcomes
We advanced R&D in breast, pancreatic and ovarian cancer diagnostics to improve patient outcomes.
Partnerships for Progress
We collaborate with doctors, researchers, and investors to expand access and drive innovation.
Scientific & Clinical Excellence
We pursue rigorous research and validation to deliver trusted, high-impact diagnostic tools.
Integrity & Governance
We uphold transparency, accountability, and strong ethical standards across all areas of our business.
Sustainable Growth
We’re committed to responsible growth that delivers long-term value for patients, partners, investors and society.
Our Laboratory
Australia
Sydney, NSW: BCAL Diagnostics NATA-accredited commercial clinical laboratory is delivering its first-in-class blood test, BREASTEST plus™, to patients in consultation with healthcare professionals.
Equipped with cutting-edge Liquid Chromatography Mass Spectrometry (LCMS) technology, the facility supports ongoing clinical research, ensures robust diagnostic performance, and enables the scalable delivery of BCAL Diagnostics non-invasive breast test for breast cancer, BREASTEST plus™.
Meet our Board of Directors
Meet Our TeamBCAL Diagnostic Limited highly experienced Board of Directors brings together proven expertise in biotechnology, diagnostics, healthcare innovation, and global business strategy. Backed by depth of knowledge in biomedical start-ups and the broader life sciences industry, they are committed to driving scientific excellence, clinical innovation, and global accessibility for BCAL’s breakthrough breast cancer screening technology.
